切换至 "中华医学电子期刊资源库"

第五届中国出版政府奖音像电子网络出版物奖提名奖

中国科技核心期刊

中国科学引文数据库(CSCD)来源期刊

中华重症医学电子杂志 ›› 2017, Vol. 03 ›› Issue (03) : 197 -201. doi: 10.3877/cma.j.issn.2096-1537.2017.03.009

所属专题: 文献

临床研究

肿瘤患者连续性肾脏替代治疗枸橼酸与低分子肝素抗凝效果及预后比较
柯昊贤1, 沈玄韬1, 余文辉1, 李梓濠1, 杨文1, 季钰尧1, 陈崇翔1, 赵擎宇1,()   
  1. 1. 510060 广州,中山大学肿瘤防治中心医院重症医学科
  • 收稿日期:2017-02-20 出版日期:2017-08-28
  • 通信作者: 赵擎宇
  • 基金资助:
    国家卫生和计划生育委员会专项基金(1311200006402)

Comparison of efficacy and prognosis between citrate and low molecular weight heparin in tumor patients undergoing continuous renal replacement therapy

Haoxian Ke1, Xuantao Shen1, Wenhui Yu1, Zihao Li1, Wen Yang1, Yuyao Ji1, Chongxiang Chen1, Qingyu Zhao1,()   

  1. 1. Department of Critical Care Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
  • Received:2017-02-20 Published:2017-08-28
  • Corresponding author: Qingyu Zhao
  • About author:
    Corresponding author: Zhao Qingyu, Email:
引用本文:

柯昊贤, 沈玄韬, 余文辉, 李梓濠, 杨文, 季钰尧, 陈崇翔, 赵擎宇. 肿瘤患者连续性肾脏替代治疗枸橼酸与低分子肝素抗凝效果及预后比较[J/OL]. 中华重症医学电子杂志, 2017, 03(03): 197-201.

Haoxian Ke, Xuantao Shen, Wenhui Yu, Zihao Li, Wen Yang, Yuyao Ji, Chongxiang Chen, Qingyu Zhao. Comparison of efficacy and prognosis between citrate and low molecular weight heparin in tumor patients undergoing continuous renal replacement therapy[J/OL]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2017, 03(03): 197-201.

目的

比较肿瘤患者行连续性肾脏替代治疗(CRRT)时选用枸橼酸或低分子肝素进行抗凝的效果以及预后。

方法

回顾性分析2012年9月至2016年10月中山大学肿瘤防治中心行CRRT治疗的117例肿瘤患者的临床资料。其中18例患者使用局部枸橼酸抗凝(枸橼酸抗凝组),99例患者使用全身性低分子肝素抗凝(低分子肝素抗凝组)。采用秩和检验比较枸橼酸抗凝组与低分子肝素抗凝组患者CRRT前凝血酶原时间(PT)、活化的部分凝血活酶时间(APTT)、血小板计数(PLT)及CRRT3 d内PT、APTT、PLT、血红蛋白浓度变化,重症监护病房(ICU)停留时间、住院时间、血滤器寿命差异。

结果

CRRT3 d内,低分子肝素抗凝组患者APTT较枸橼酸抗凝组患者延长,两组患者APTT变化差异有统计学意义[9.11(3.90,9.11)s vs -0.94(-3.40,3.38)s,Z=-4.001,P<0.001];枸橼酸抗凝组患者血滤器寿命长于低分子肝素抗凝组患者,且差异有统计学意义[29.64(19.47,38.94) h vs 17.00(9.50,24.40)h,Z=-3.468,P=0.001]。而两组患者出血发生率、CRRT3 d内PT、PLT、血红蛋白浓度变化差异均无统计学意义。且两组患者住院时间、ICU停留时间以及死亡率差异均无统计学意义。

结论

在肿瘤患者行CRRT时使用枸橼酸较低分子肝素抗凝效果更佳。

Objective

To compare the effect of citrate on anticoagulation efficacy and outcome with low molecular weight heparin during continuous renal replacement treatment (CRRT) in cancer patients.

Methods

Retrospectively analyze the clinical data of 117 patients admitted in intensive care unit (ICU) of Sun Yat-sen University Cancer Center and received CRRT from September 2012 to October 2016. Among all patients, 18 patients received citrate (TCG group), while other 99 patients received low molecular heparin treatment (THG group). Rank-sum test was used to compare prothrombin time (PT), active partial thromboplastin time (APTT), blood platelet (PLT) count before CRRT. In addition, the change of PT, APTT, PLT, hemoglobin concentration during the first three days after CRRT, the stay of ICU and hospital and the filter life were also analyzed.

Results

In three days after CRRT, APTT in THG group was significant longer than patients in TCG group and there was a significant difference of APTT change between two groups [9.11(3.90, 9.11) s vs -0.94(-3.40, 3.38) s, Z=-4.001, P<0.001]. The filter life in TCG group was significant longer than that in THG group [29.64(19.47, 38.94) h vs 17.00(9.50, 24.40) h, Z=3.468, P=0.001]. However, there was no significant difference of PT, PLT, hemoglobin concentration change in 3 days after CRRT between two groups. What′s more, there was no difference of incidence of bleeding, length of ICU and hospital stay, and mortality, either.

Conclusion

In cancer patients, citrate had a better anticoagulation efficacy than low molecular weight heparinduring CRRT.

表1 枸橼酸抗凝组与低分子肝素抗凝组患者一般临床资料比较
表2 枸橼酸抗凝组与低分子肝素抗凝组患者CRRT前主要凝血功能比较[MQR)]
表3 枸橼酸抗凝组与低分子肝素抗凝组患者CRRT3 d内凝血功能变化及预后比较
1
Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism[J]. Lancet Oncol, 2005, 6(6): 401-410.
2
Lee AY, Levine MN. Venous thromboembolism and cancer: Risks and outcomes[J]. Circulation, 2003, 107(23 Suppl 1): Ⅰ17-Ⅰ21.
3
Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: ImprovingGlobal Outcomes (KDIGO)[J]. Kid Int, 2011, 80 (6): 572-586.
4
Webb AR, Mythen MG, Jacobsen D, et al. Maintaining blood flow in the extracorporeal circuit: haemostasis and anti- coagulation[J]. Intensive Care Med, 1995, 21(1): 84-83.
5
Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding[J]. Kidney Int, 1999, 55(5): 1991-1997.
6
Mehta RL, McDonald BR, Aguilar MM, et al. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients[J]. Kidney Int, 1990, 38(5): 976-981.
7
Liu C, Mao Z, Kang H, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials[J]. Crit Care, 2016, 20(1): 144.
8
Santiago MJ, López-Herce J, Urbano J, et al. Complications of continuous renal replacement therapy in critically ill children: a prospective observational evaluation study[J]. Crit Care, 2009, 13(6): R184.
9
Liao YJ, Zhang L, Zeng XX, et al. Citrate versus unfractionated heparin for anticoagulation in continuous renal replacement therapy[J]. Chin Med J (Engl), 2013, 126(7): 1344-1349.
10
Tas F, Kilic L, Duranyildiz D. Coagulation tests show significant differences in patients with breast cancer[J]. Tumour Biol, 2014, 35(6): 5985-5992.
11
Khorana AA. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients[J]. Oncologist, 2007, 12 (11): 1361-1370.
12
Bai M, Zhou M, He L, et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs[J]. Intensive Care Med, 2015, 41(12): 2098-2110.
13
Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy[J]. Intensive Care Med, 2012, 38(1): 20-28.
14
Oudemans-van Straaten HM, Ostermann M. Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice[J]. Crit Care, 2014, 18(4): 249.
15
Morgera S, Scholle C, Voss G, et al. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience[J]. Nephron Clin Pract, 2004, 97(4): c131-c136.
16
Su K, Chen F, Yan WM, et al. Fibrinogen-like protein 2/fibroleukinprothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma[J]. World J Gastroenterol, 2008, 14(39): 5980-5989.
17
Venkataraman R, Kellum JA. Defining acute renal failure: the RIFLE criteria[J]. J Intensive Care Med, 2007, 22(4): 187-193.
18
Stucker F, Ponte B, Tataw J, et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial[J]. Crit Care, 2015, 19: 91.
19
Gutierrez-Bernays D, Ostwald M, Anstey C, et al. Transition From Heparin to Citrate Anticoagulation for Continuous Renal Replacement Therapy: Safety, Efficiency, and Cost[J]. Ther Apher Dial, 2016, 20(1): 53-59.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[7] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[8] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[9] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[10] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[11] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[12] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[13] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[14] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?